angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
These actions, including weak DAT inhibition combined with secondary catecholaminergic, orexinergic, glutamatergic, and GABAergic modulation, are thought to underlie modafinil's ability to promote wakefulness and cognitive function with a lower risk of euphoria and abuse than traditional amphetamine-like psychostimulants. From laboratory research, modafinil has little to no affinity for serotonin or norepinephrine transporters and does not directly interact with these systems. However, studies have shown that elevated concentrations of norepinephrine and serotonin can occur as an indirect effect following modafinil administration due to increased extracellular dopamine activity. Unlike traditional psychostimulant drugs, such as cocaine or amphetamine, modafinil shows low potential for causing euphoria due to differences in how it interacts with dopamine transporters at a cellular level. In addition to its influence on dopaminergic pathways, modafinil may impact other neurotransmitter systems, such as orexin (hypocretin) and histamine. Orexinergic and histaminergic neurons are involved in promoting wakefulness and regulating arousal states. Modafinil may increase signaling within hypothalamic orexin and histamine pathways, potentially contributing to its wake-promoting effects. In animal models, modafinil-induced increases in hypothalamic histamine release require intact orexinergic neurons. The wake-promoting effects of modafinil do not appear to depend on the orexin system.
=== 21 January === The Sudanese Revolutionary Front expelled the United Popular Front from its member groups after the UPF accused the alliance of being unduly influenced by the RSF. SAF units besieged at the Signal Corps garrison in Khartoum Bahri launched their first major offensive since September 2024, forcing the RSF to withdraw east towards the Kafouri neighborhood. The SAF also retook Abboud Park in Khartoum Bahri and the Juwayriyah School and the African Council Schools in Al Safiya district. The RSF issued a 48-hour ultimatum for the SAF to withdraw from El Fasher.
compared four sterile wound-cleansing solutions (saline, Ringer's solution, Prontosan® and Octenisept®) using a wound coating model consisting of slides containing dried blood plasma or fibrin. The concentration of dissolved proteins was measured and the findings indicate that a surfactant containing solution (polyhexamethylene biguanide with betaine) (Prontosan®) was more effective than saline in removing the protein (adhered dried plasma or fibrin). The proteins in the antiseptic solution (Octenisept®) were denatured and became insoluble. The authors suggest this implies that the antiseptic solution is unsuitable as a 'general' wound cleanser and that its use should be restricted to infected wounds. In a double-blind, randomised, stratified, controlled, parallel-group study the influence of two antiseptics (octenidine, polyhexanide) versus a placebo of Ringer's solution on wound healing in a porcine model was conducted. Assessment of healing was recorded using planimetry and histopathology. At nine days post wounding, the octenidine-treated wounds demonstrated retarded contraction at significantly greater extent than placebo and polyhexanide. At days 18 and 28 the polyhexanide treated wounds supported contraction significantly more than placebo and octenidine. The polyhexanide treated wounds led to complete wound closure after 22.9 days, in comparison to the placebo octenidine treated wounds respectively, 24.1 days (p < 0.05) and 28.3 days (no statistical difference to placebo).
Although many of the largest restaurant chains in Canada are US-based (such as McDonald's and Yum! Brands among others), some Canadian-based (owned and operated from Canada) restaurant chains are growing and have expanded into other markets, especially into the US.
Sources: en.wikipedia.org
In a prebiotic context, they argued that seawater would likely still be buffered and ferrous iron could inhibit oxidation. Steam and hydrogen sulfide. In 1999, after Miller suffered a stroke, he donated the contents of his laboratory to Bada. In an old cardboard box, Bada discovered unanalyzed samples from modified experiments that Miller had conducted in the 1950s. In a "volcanic" apparatus, Miller had amended an aspirating nozzle to shoot a jet of steam into the reaction chamber. Using high-performance liquid chromatography and mass spectrometry, Bada's lab analyzed old samples from a set of experiments Miller conducted with this apparatus and found some higher yields and a more diverse suite of amino acids. Bada speculated that injecting the steam into the spark could have split water into H and OH radicals, leading to more hydroxylated amino acids during Strecker synthesis. In a separate set of experiments, Miller added hydrogen sulfide (H2S) to the reducing atmosphere, and Bada's analyses of the products suggested order-of-magnitude higher yields, including some amino acids with sulfur moieties. Free electrons and charged microdroplets. A 2021 work highlighted the importance of the high-energy free electrons present in the experiment. It is these electrons that produce ions and radicals, and represent an aspect of the experiment that needs to be better understood. A 2025 study used charges from sprays of water instead of lightning to produce electricity.
== Uses == The plant is used in the traditional medicine of Indonesia, Malaysia and Vietnam where the root of the plant is boiled in water, and the water is consumed as a tonic. The flower and fruits are used to treat dysentery, and the root is used for malaria, fever, and other ailments.
=== Embryos === Embryos take 8–12 months to develop due to temperature variations in the environment. The catshark lays eggs in their blastodisc form. The following exhibits a typical developmental timeline (measurements are embryo length):
Sources: en.wikipedia.org
==== Hypogonadism ==== An absolute deficiency in androgen production due to primary or secondary hypogonadism can cause gynecomastia. Primary hypogonadism results when there is damage to the testes (due to radiation, chemotherapy, infections, trauma, etc.), leading to impaired androgen production. It can also be caused by chromosomal abnormality seen in Klinefelter syndrome, which is associated with gynecomastia in about 80% of cases. Secondary hypogonadism results when there is damage to the hypothalamus or pituitary (due to radiation, chemotherapy, infection, trauma, etc.), and similarly leads to impaired androgen production. The net effect is reduced androgen production while serum estrogen levels (from peripheral aromatization of androgens) remain unaffected. The lack of androgen-mediated inhibition of breast tissue proliferation, combined with relative estrogen excess, results in gynecomastia.
=== Sensory === PDL is heavily innervated; it involves mechanoreception, nociception and reflexes. Periodontal mechanoreceptors are present in PDL. They will transmit information about the stimulated tooth, direction and amplitude of forces.
: equilibrium In order to meet the thermodynamic condition for equilibrium, the Gibbs energy must be stationary, meaning that the derivative of G with respect to the extent of reaction, ξ, must be zero. It can be shown that in this case, the sum of chemical potentials times the stoichiometric coefficients of the products is equal to the sum of those corresponding to the reactants. Therefore, the sum of the Gibbs energies of the reactants must be the equal to the sum of the Gibbs energies of the products.
13 July to 15 August The 2nd Brigade, 101st Airborne Division and ARVN 54th Regiment, 1st Division launched Operation Campbell Streamer in the Bạch Mã area near Huế. The operation results in 51 PAVN killed and one captured.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.